The SERENA-6 trial reveals camizestrant's potential to improve outcomes in hormone receptor (HR)-positive, HER2-negative breast cancer by utilizing circulating tumor DNA (ctDNA)-guided therapy towards ESR1 mutations before disease progression. Read More ›

Patient-reported outcomes from EMBER-3 demonstrate that imlunestrant improves global health status/quality of life and physical function in patients with ESR1 mutations in estrogen receptor (ER)-positive, HER2-negative advanced breast cancer. Read More ›

In this fourth installment, Paula reviews relevant data for immunotherapies currently FDA approved for patients with advanced endometrial cancer. Read More ›

In this third installment, Paula will discuss the importance and relevance of data science in advancing the field of nursing. Read More ›

In this first installment, Paula will discuss recent data of immunotherapy in patients with advanced endometrial cancer and highlight nursing considerations to help manage side effects. Read More ›

In this second installment, Paula will discuss a health equity study investigating the association of neighborhood socioeconomic deprivation in patients with gynecologic cancers. Read More ›

Dr Erica Mayer explains the results of a study utilizing the novel SERD SIM0270, as monotherapy and in combination, in the treatment of patients with estrogen receptor–positive, HER2-negative advanced breast cancer. Read More ›

Dr Erica Mayer discusses an analysis of the EMERALD study, which explores the effects of variant allele frequencies on outcomes for patients with advanced breast cancer being treated with elacestrant. Read More ›

Dr Erica Mayer comments on real-world outcomes for elacestrant derived from the GuardantINFORM database, and describes which patients elacestrant therapy may be best for. Read More ›

Dr Erica Mayer discusses the positive results of the EMBER-3 trial, and the impact that imlunestrant will have on the treatment of patients with advanced breast cancer Read More ›